Seminars in Oncology
Volume 33 , Pages 13-17 , April 2006

Management of Cancer-Treatment–Induced Bone Loss in Postmenopausal Women Undergoing Adjuvant Breast Cancer Therapy: A Z-FAST Update

  • Adam Brufsky

      Affiliations

    • Dr Brufsky has received research grant support and honoraria from Novartis.
    • Corresponding Author InformationAddress correspondence and reprint requests to: Adam Brufsky, MD, PhD, Magee/UPCI Breast Program, University of Pittsburgh Cancer Institute, 300 Halket St, Suite 4628, Pittsburgh, PA 15213-3180.

References 

  1. Aapro MS . Long-term implications of bone loss in breast cancer . Breast . 2004;13:S29–S37
  2. Pfeilschifter J , Diel IJ . Osteoporosis due to cancer treatment (Pathogenesis and management) . J Clin Oncol . 2000;18:1570–1593
  3. Gnant M , Jakesz R , Mlineritsch B , et al.   Zoledronic acid inhibits cancer treatment-induced bone loss in premenopausal patients with breast cancer who are receiving adjuvant endocrine treatment . Breast . 2005;14:S44; (abstr)
  4. Mackey JR , Joy AA . Skeletal health in postmenopausal survivors of early breast cancer . Int J Cancer . 2005;114:1010–1015
  5. Winer EP , Hudis C , Burstein HJ , et al.   American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer (Status report 2004) . J Clin Oncol . 2005;23:619–629
  6. Coombes RC , Hall E , Gibson LJ , et al.   A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer . N Engl J Med . 2004;350:1081–1092 [Erratum in: N Engl J Med 351:2461, 2004]
  7. Goss PE , Ingle JN , Martino S , et al.   A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer . N Engl J Med . 2003;349:1793–1802
  8. Baum M , Buzdar A , Cuzick J , et al.   Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer (Results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses) . Cancer . 2003;98:1802–1810
  9. Delea TE , McKiernan JM , Brandman J , et al.   Effects of skeletal complications on total medical care costs in patients with bone metastases of solid tumors . (abstr) Proc Am Soc Clin Oncol . 2005;23(suppl):752S
  10. Harvey HA . Optimizing bisphosphonate therapy in patients with breast cancer on endocrine therapy . Semin Oncol . 2004;31(suppl 12):23–30
  11. Brufsky A , Harker G , Beck T , et al.   Zoledronic acid (ZA) for prevention of cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW with early breast cancer (BCa) receiving adjuvant letrozole (Let) (preliminary results of the Z-FAST trial) . 2004; Presented at the 27th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8, (abstr 1114)
  12. Howell A  ATAC Trialists Group . Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer . Lancet . 2005;365:60–62
  13. ATAC Trialists’ Group Houghton J . Using anastrozole as initial adjuvant treatment prevents early recurrences and reduces adverse events (Updated data from the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial) . (abstr) Proc Am Soc Clin Oncol . 2005;23(suppl):S24
  14. Boccardo F . Switching trial of adjuvant tamoxifen with an aromatase inhibitor in postmenopausal patients with breast cancer . Clin Breast Cancer . 2004;5(suppl 1):S13–S17
  15. Jakesz R , Jonat W , Gnant M , et al.  ABCSG, the GABG   Switching of postmenopausal women with endocrine responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen (combined results of ABCSG trial 8 and ARNO 95 trial) . Lancet . 2005;366:455–462
  16. Thürlimann B , Keshaviah A , Coates AS , et al.  Breast International Group (BIG) 1-98 Collaborative Group   A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer . N Engl J Med . 2005;353:2747–2757
  17. Coombes RC , Hall E , Snowdon CF , et al.   The Intergroup Exemestane Study (A randomized trial in postmenopausal patients with early breast cancer who remain disease-free after two to three years of tamoxifen-updated survival analysis) . (abstr) Breast Cancer Res Treat . 2004;88(suppl):S7
  18. Coleman RE , Banks LM , Hall E , et al.   Intergroup Exemestane Study (1 year results of the bone sub-protocol) . 2004; Presented at the 27th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8, (abstr 401)
  19. Goss PE , Ingle JN , Martino S , et al.   Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer (Updated findings from NCIC CTG MA.17) . J Natl Cancer Inst . 2005;97:1262–1271
  20. Reid IR , Brown JP , Burckhardt P , et al.   Intravenous zoledronic acid in postmenopausal women with low bone mineral density . N Engl J Med . 2002;346:653–661
  21. Gnant M . Zoledronic acid effectively counteracts cancer treatment induced bone loss (CTIBL) in premenopausal breast cancer patients receiving adjuvant endocrine treatment with goserelin plus anastrozole versus goserelin plus tamoxifen - Bone density subprotocol results of a randomized multicenter trial (ABCSG-12) . 2004; Presented at the 27th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8, (abstr 6)
  22. Brufsky A , Harker G , Beck T , et al.   Zoledronic acid (ZA) effectively inhibits cancer treatment-induced bone loss (CTIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant Letrozole (Let) (12 mos BMD results of the Z-FAST trial) . 2005; Proc Am Soc Clin Oncol 23:16S, (abstr). Available at: http://www.asco.org/ac/1,1003,_12-00251100_18-0034-00_19-004309,00.asp
  23. Davidson N , Neven P , Llombart A , et al.   Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer . (abstr) Breast . 2005;14(suppl):S44
  24. Hillner BE , Ingle JN , Chlebowski RT , et al.   American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer . [Erratum in: J Clin Oncol 22:1351, 2004] J Clin Oncol . 2003;21:4042–4057

PII: S0093-7754(06)00164-3

doi: 10.1053/j.seminoncol.2006.03.022

Seminars in Oncology
Volume 33 , Pages 13-17 , April 2006

Article Tools

* Image Usage & Resolution